Start free trial

Latest Bambusa Therapeutics News & Updates

See the latest news and media coverage for Bambusa. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Bambusa Therapeutics (Bambusa)

Clinical-stage biotechnology company

bambusatx.com
Headquarters
BOSTON, United States
Founded year
2024
Company type
Private company
Number of employees
23–50
Industry
Pharmaceuticals

Last updated

Latest news about Bambusa Therapeutics (Bambusa)

In short: Bambusa reported positive BBT001 atopic dermatitis results, initiated subcutaneous dosing, and filed for an IPO.

Company announcements

Bambusa

Bambusa reports positive Phase 1 data and begins new trial

The antibody showed depletion of eosinophils, and the Phase 1b/2a trial is for chronic rhinosinusitis with nasal polyps.

Unlock all announcements with a

Media coverage

Stock Titan

BBTX Stock News

Recent: Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering. Track all BBTX press releases, SEC filings ...

Dermatology Times

BBT001 Bispecific Antibody Demonstrates Fast AD Clearance and Long-Lasting Itch Relief in Phase 1 Trial | Dermatology Times

Phase 1 results show Bambusa Therapeutics’ BBT001 quickly reduces atopic dermatitis and itch, sustains type 2 biomarker suppression, and may enable quarterly dosing.

Unlock all articles with a

Never miss news about Bambusa

Track Bambusa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Bambusa competitors & trending companies

Browse news for competitors to Bambusa and other trending companies.